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Abstract
Introduction
Gynecomastia and/or mastodynia is a common medical problem in patients receiving anti-
androgen (bicalutamide or flutamide) treatment for prostate cancer; up to 70% of these
patients result to be affected; furthermore, this can jeopardise patients’ quality of life.
Aims
To systematically review the quality of evidence of the current literature regarding treatment
options for bicalutamide-induced gynecomastia, including efficacy, safety and patients’
quality of life.
Methods
The PubMed, Medline, Scopus, The Cochrane Library and SveMed+ databases were sys-
tematically searched between January 1, 2000 and December 31, 2014. All searches were
undertaken between January and February 2015. The search phrase used was:”gyneco-
mastia AND treatment AND prostate cancer”. Two reviewers assessed 762 titles and
abstracts identified. The search and review process was done in accordance with the
PRISMA statement. The PICOS (patients, intervention, comparator, outcomes and study
design) process was used to specify inclusion criteria. Quality of evidence was rated
according to GRADE.
Main OutcomeMeasures
Primary outcomes were: treatment effects, number of complications and side effects. Sec-
ondary outcome was: Quality of Life.
Results
Eleven studies met the inclusion criteria and are analysed in this review. Five studies
reported pharmacological intervention with tamoxifen and/or anastrozole, either as
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prophylactic or therapeutic treatment. Four studies reported radiotherapy as prophylactic
and/or therapeutic treatment. Two studies compared pharmacological treatment to radio-
therapy. Most of the studies were randomized with varying risk of bias. According to
GRADE, quality of evidence was moderate to high.
Conclusions
Bicalutamide-induced gynecomastia and/or mastodynia can effectively be managed by oral
tamoxifen (10–20 mg daily) or radiotherapy without relevant side effects. Prophylaxis or
therapeutic treatment with tamoxifen results to be more effective than radiotherapy.
Introduction
Androgen deprivation therapy (ADT) is a therapeutic treatment recommended for asymptom-
atic patients with high risk, locally advanced (T3–4 or N+, M0) prostate cancer (PC). ADT is
also recommended as a long-term adjuvant treatment, either isolated, or combined with exter-
nal beam radiotherapy (EBRT), for node-positive (N+) patients. Surgical or medical castration,
using luteinizing hormone-releasing hormone (LHRH) agonists, is recommended for meta-
static (M1) prostate cancer. Antiandrogen treatment is recommended as a short-term treat-
ment for patients receiving LHRH agonists. Bicalutamide is the most used nonsteroidal
antiandrogen [1].
A very common side effect of antiandrogen treatment is the development of gynecomastia
and/or mastodynia, sometimes referred to as bicalutamide-induced breast events (BEs) [1,2].
These side effects are due to an imbalance between estrogens and androgens in the breast tissue
[3]. Stimulation of estrogen receptors in the breast tissue leads to growth; at the contrary, stim-
ulation of androgen receptors inhibits this effect. Nonsteroidal antiandrogens block androgen
receptors, which leads to increased secretion of luteinizing hormone (LH) by means of the
feedback mechanism. Subsequently, increased LH stimulates testosterone secretion, which is
then converted to estrogen by means of peripheral aromatization. The blockade of androgen
receptors also increases the estrogens stimulatory effect on the breast tissue, as the androgen
inhibitory effect is removed [4].
The cumulative prevalence of both these side effects can be as high as 70% [1,2]; this leads
patients to discontinue antiandrogen treatment in 16.4% of cases [1]. According to various
studies, in fact, gynecomastia can have a strong negative impact on patient’s Quality of Life
(QoL). This is partly due to the loss of a male appearance [5,6]. Also, there have been reports of
tamoxifen causing sexual impotence in male breast cancer patients, with negative effects on
QoL [7].
Classifications of gynecomastia, as reported in literature, are based on: appearance of the
breast, composition ratio between fat and glandular tissue, or a combination. In order to assist
in the diagnosis process, ultrasound and mammography are often used [8].
Gynecomastia and mastodynia can be managed by pharmacological treatments, surgical, as
well as by low-dose radiotherapy (RT) of the breast tissue.
Pharmacological methods aimed at preventing or treating gynecomastia include the anties-
trogen tamoxifen and the aromatase inhibitor anastrozole [2,7,9–16]. Tamoxifen aims at
reducing estrogens effect in breast tissue by blocking the estrogen receptors. Anastrozole aims
at reducing the peripheral aromatization of androgens into estrogen, and thereby reducing the
estrogen effect on breast tissue [4]. RT prevents gynecomastia by inducing hypoplasia or
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aplasia in the irradiated tissue. There is also a reduction in the number of ducts in irradiated
breasts [14].
Aims
To systematically review the quality of evidence of the current literature regarding treatment
options for antiandrogen induced gynecomastia, including efficacy, safety and patients’QoL.
Methods
Information sources
Studies were identified by searching systematically in the electronic databases PubMed, Med-
line, Scopus, The Cochrane Library and SveMed+. The search phrase used was: “gynecomastia
AND treatment AND prostate cancer”. The search and review process was done in accordance
with the PRISMA statement. Searches were restricted to articles in the English language pub-
lished after 2000. All searches were undertaken between January and February 2015. No regis-
tered review protocol exists.
Study selection and data collection process
We searched for, and assessed studies comparing different treatment regimes for antiandrogen
associated gynecomastia. Pharmacological treatment, RT and surgery were accepted. Both pro-
phylactic and therapeutic treatments were accepted. Studies to be included in this review had
to match predetermined criteria according to the PICOS approach. Criteria for inclusion and
exclusion are specified in Table 1. No limitations were applied on ethnicity, age of patients or
stage of prostate cancer. Studies reporting gynecomastia with other etiology were excluded as
they are reported in a separate study [8].
Two reviewers independently screened all search results, titles and abstracts, in order to find
studies matching the predetermined inclusion criteria. Any apprehension was resolved by dis-
cussion. The data from included studies were extracted to an extraction form. Search process
and reasons for exclusion are presented in a flow diagram (S1 Fig).
Quality assessment strategy and risk of bias
The included studies have been assessed for bias in order to evaluate validity and risk for over-
or under-estimating the true intervention effect. To determine the risk of bias, one reviewer
assessed all the included studies by using the Cochrane Collaboration's 'Risk of bias' tool. This
Table 1. PICOS criteria for inclusion and exclusion of studies.
Parameter Inclusion criteria Exclusion criteria
Patients Patients of any age with prostate cancer/treatment associated
gynecomastia
Other types of gynecomastia
Intervention Pharmacological, surgical or radiotherapeutic treatments
Comparator How effective are the different treatment methods
Outcomes Primary outcome measures: Treatment results and number of
complications/side effects. Secondary outcome measures: QoL
Study
design
Randomized controlled trials, non-randomized controlled trials,
retrospective, prospective, or concurrent cohort studies. At least 20
patients. At least 1 year follow-up. Published in English.
Reviews, expert opinion, comments, letter to editor, case reports,
studies on animals, conference reports. Less than 20 patients.
Shorter follow-up than 1 year. Studies with no outcomes reported.
Published before 2000. Published in any other language than
English.
doi:10.1371/journal.pone.0136094.t001
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tool provides support for judging specific features of a study in a specific 'Risk of bias' table. In
Table 2 each entry can be assessed as: 'low risk', 'high risk' or 'unclear risk'. 'Unclear risk' indi-
cates lack of information in a study or uncertainty for risk of bias [17] (Table 2).
The evidence across included studies was rated using the GRADE system. This system is
designed for reviews and guidelines that examine different treatments or interventions. Using
pre-specified criteria quality of evidence can be rated by assessing risk of bias (“internal valid-
ity”), directness and precision (“external validity”) [18]. The quality of evidence for each out-
come measure was assessed to be: very low, low, moderate, or high (Table 3).
Main outcome measures
Primary outcomes were: treatment effects, number of complications/side effects. Secondary
outcomes were: QoL.
Table 2. Risk of bias according to The Cochrane Collaboration's 'Risk of bias' tool.
Publi-cation Ran-dom
sequ-ence
genera-tion
Allo-cation
conceal-
ment
Blin-ding of
partici-pants
and personnel
Blin-ding of
out-come
assess-ment
Incom-
plete out-
come data
Selec-tive
repor-ting
Other sources for
bias
Sum-
mary
Ser-retta et al.
[2]
Unclear Yes Unclear Unclear Yes Unclear Co-authors employed
by Astra-Zeneca
Unclear
risk of bias
Bedog-netti
et al. [9]
Yes Yes No No Yes Unclear High risk
of bias
Fradet et al.
[10]
Yes Yes Yes Yes Yes Unclear Funding by Astra-
Zeneca
Low risk of
bias
Saltz-stein
et al. [4]
Yes Yes Yes Yes Yes Unclear Co-authors employed
by Astra-Zeneca
Low risk of
bias
Boc-cardo
et al. [7]
Yes Unclear Yes Yes Yes Unclear Funding by Astra-
Zeneca
Unclear
risk of bias
Ozen et al. [11] Unclear Yes No No Yes Unclear High risk
of bias
Van Poppel
et al. [12]
No No No No Yes Unclear Sponsored by Astra-
Zeneca
High risk
of bias
Tyrrell et al.
[13]
Yes Yes Yes Yes Yes Unclear Funding by Astra-
Zeneca. Co-authors
employed by Astra-
Zeneca
Low risk of
bias
Wid-mark et al.
[14]
Unclear Unclear No No Yes Unclear High risk
of bias
Per-doná et al.
[15] Di Loren-
zo et al. [16]
Yes Yes No No Yes Unclear High risk
of bias
doi:10.1371/journal.pone.0136094.t002
Table 3. GRADE analysis and definition.
Quality of
evidence
Definition
High We are very confident that the true effect lies close to that of the estimate of the effect
Moderate We are moderately confident in the effect estimate: The true effect is likely to be close
to the estimate of the effect, but there is a possibility that it is substantially different
Low Our confidence in the effect estimate is limited: The true effect may be substantially
different from the estimate of the effect
Very low We have very little confidence in the effect estimate: The true effect is likely to be
substantially different from the estimate of effect
doi:10.1371/journal.pone.0136094.t003
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Results
A total of 762 titles and abstracts were obtained through the systematic literature search. After
a preliminary screening, 24 duplicates and 694 studies that clearly did not match inclusion cri-
teria were removed. 44 abstracts and full texts were examined in respect to inclusion criteria.
11 studies met inclusion criteria and were included in this review.
Validity of included studies
The validity of the included studies is presented in Table 2.
Main outcome measures
Bicalutamide (or flutamide) treatment is highly associated with gynecomastia and/or mastody-
nia; prevalence of these side effects can be as high as 70%. These are predictable side effects that
can be prophylactically managed either by pharmacological treatment or RT.
If no prophylactic treatment has been initiated, therapeutic treatment with drugs or RT can
be started on the onset of symptoms [2,7,9–16].
Seven studies included patients with T1 or T1b—T3–4, any N and M0 [4,10,11–13,15,16].
Three studies included patients with non-metastatic, local or locally advanced PC [2,7,14]. One
study provided no information on staging but excluded metastatic PC [9].
Primary and secondary outcomes are summarized in Tables 4 and 5. Table 4 summarizes
treatment effects, both pharmacological treatment with either tamoxifen and/or anastrozole,
and RT. Side effects and complications are also presented in Table 4 [2,7,9–16]. Table 5 sum-
marizes QoL following gynecomastia treatment [10,15,16].
Drug therapy
The antiestrogen tamoxifen and the aromatase inhibitor anastrozole have both been used as
pharmacological treatments, either as prophylactic or therapeutic regimens.
Prophylactic treatment with tamoxifen, 10–20 mg daily started simultaneously as bicaluta-
mide treatment, is highly effective in preventing both gynecomastia and mastodynia
[2,4,7,9,10]. Six studies investigated the use of tamoxifen as prophylactic treatment. All studies
reported a reduction in BEs. Three studies reported a prevalence of BEs ranging from 8.8% to
44% following prophylactic treatment [2,9,10]. Saltzstein et al. reported that patients receiving
tamoxifen were 3.22 times less likely to develop BEs [4]. Boccardo et al. [7] reported that pro-
phylactic administration of tamoxifen reduced the risk of developing gynecomastia and/or
mastodynia by seven and six times, respectively, when compared to a control group. Prophy-
lactic treatment with tamoxifen was also reported to be safe and generally well tolerated [2,7,9];
again, Boccardo et al. [7] reported side effects in 35% of the studied population.
Prophylactic treatment with anastrozole conversely failed to provide similar benefits in
reducing BEs. Saltzstein et al. [4] reported anastrozole to provide no advantage over placebo.
Boccardo et al. [7] reported that anastrozole, compared to tamoxifen, was five times less effi-
cient on gynecomastia and four times less efficient on mastodynia. Moreover, treatment with
anastrozole resulted in twice as many side effects when compared to tamoxifen [7].
Two studies reported tamoxifen as therapeutic treatment. Saltzstein et al. [4] reported that
65.4% of patients who received therapeutic treatment with tamoxifen, 20 mg daily, experienced
resolution of gynecomastia and/or mastodynia. In the same study the control group developed
BEs, and therefore 88.8% of these patients received tamoxifen: resolution occurred in 71% of
treated subjects [4]. Serretta et al. [2] compared therapeutic tamoxifen treatment with tamoxi-
fen prophylaxis. Authors found a statistically significant difference where therapeutic
Gynecomastia in Patients with Prostate Cancer
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Table 4. Primary outcomes.
Publication Design Intervention and results Side effects
Serretta et al. [2] Randomized,
multicentre trial
Arm A: tamoxifen therapy reduced BEs to 28% of
patients (P < 0.001). Arm B: tamoxifen prophylaxis gave
significant reduction of BEs to 44% (P < 0.001).
Arm A: 2.4% discontinued tamoxifen and
3.6% discontinued bicalutamide. Arm B: 2.5%
discontinued both treatments.
Bedognetti et al. [9] Randomized,
multicentre phase 3
trial
Arm A: daily tamoxifen prophylaxis resulted in 31.7%
developing gynecomastia (P < 0.0001) and 12.2%
mastalgia (P = 0.001). Arm B: tamoxifen weekly after 8
weeks of daily treatment resulted in 74.4% developing
gynecomastia (P < 0.0001) and 46.1% mastalgia
(P = 0.001).
Arm A: 24%. Arm B: 22%
Fradet et al. [10] Randomized, double-
blind, multicentre trial
Arm A: increased doses of tamoxifen daily decreased
the number of BEs, compared to placebo, ranging from
86.2% in the 1 mg group to 8.8% in the 20 mg group
(P ! 0.0002). Arm B: placebo, 96.7% experienced BEs.
Arm A: 19.8% withdrew. Arm B: 16.7%
(bicalutamide monotherapy)
Saltzstein et al. [4] Randomized, double-
blind, multicentre trial
Arm A: tamoxifen prophylaxis patients were significantly
(3.22 times) less likely to develop gynecomastia and/or
mastodynia (relative risk estimate, 95% CI 1.28, 7.69).
The difference between the anastrozole group and the
placebo group was not significant (P = 0.749).
Therapeutic treatment gave resolution of gynecomastia
and/or mastodynia in 65.4% in the tamoxifen group and
18.8% in the anastrozole group. Arm B: placebo, 88.8%
later received tamoxifen due to BEs. This treatment
significantly reduced gynecomastia and/or mastodynia in
71.8%.
13.2% withdrew. 0.9% (one patient) withdrew
due to increased serum AST and ALT levels.
Boccardo et al. [7] Randomized, double-
blind, multicentre trial
Arm A: 10% of the tamoxifen group and 51% of the
anastrozole developed gynecomastia (P < 0.001); 6% of
the tamoxifen group and 27% of the anastrozole group
experienced mastodynia (P = 0.006). Arm B: control,
73% developed gynecomastia (P < 0.001) and 39%
experienced mastodynia (P = 0.006).
Arm A: 35.1%% of the tamoxifen group and
69.5% of the anastrozole group. Arm B:
37.5%
Ozen et al. [11] Randomized, multi-
institutional trial
Arm A: prophylactic RT resulted in 15.8% (P < 0.001)
developing gynecomastia and 36.4% mastodynia. Arm
B: control, 50.8% (P < 0.001) developed gynecomastia
and 49.2% breast pain.
Arm A: 11.3% (related to bicalutamide). Arm
B: 11.1% (related to bicalutamide).
Van Poppel et al.
[12]
Open label,
multicentre study
Arm A: therapeutic RT resulted in 36.6% experienced
improved or resolved gynecomastia and mastodynia;
22% had no change and 24.4% experienced worsening
of symptoms.
Arm A: 43.9%. All RT related side effects
were transient.
Tyrrell et al. [13] Randomized, double-
blind, multicentre trial
Arm A: prophylactic RT resulted in an incidence of
gynecomastia between 50% and 52% (OR 0.13, 95% CI
0.04, 0.38, P <0.001). Arm B: sham RT resulted in an
incidence of gynecomastia between 81% and 85% (OR
0.13, 95% CI 0.04, 0.38, P <0.001).
Arm A: 33% (RT related), all of which were
short-lived. Arm B: 2% (RT related).
Widmark et al. [14] Randomized,
Scandinavian trial
Arm A: prophylactic RT resulted in an incidence of
gynecomastia between 28% and 44%. Breast
tenderness was reported in 43% of patients (P < 0.001).
Arm B: control, incidence of gynecomastia between 71%
and 78%. Breast tenderness reported in 75% of patients
(P < 0.001).
Some patients reported skin irritation
Perdonà et al. [15]
Di Lorenzo et al.
[16]
Randomized,
multicentre trial
Arm A: prophylactic RT resulted in 34% developing
gynecomastia (OR 0.51, P = 0.008) and 30%
mastodynia (OR 0.43, P = 0.02). Arm B: tamoxifen daily
resulted in 8% developing gynecomastia (OR 0.1, 95%
CI, P = 0.0009) and 6–7% breast pain (OR 0.1,
P = 0.009). Arm C: control, 67–70% developed
gynecomastia and 57–58% mastodynia. Tamoxifen later
significantly reduced gynecomastia and mastodynia in
arm C (OR 0.2, P = 0.02)
Arm A: highest number of side effects where
19–40% experienced short-lived skin
irritations, rashes or nipple erythema.
doi:10.1371/journal.pone.0136094.t004
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treatment reduced the prevalence of BEs to 28%, while prophylaxis reduced the prevalence to
35% [2].
Taking these findings together, tamoxifen results to be more effective than anastrozole in
both preventing and treating gynecomastia and mastodynia. Tamoxifen is most effective when
administered daily; when switching to a weekly schedule, instead, the preventive effect declined
[9]. There seems to be a dose-response relationship between the administered dose and the
level of BEs. Fradet et al. reported that increased doses of tamoxifen, from 1 mg to 20 mg,
decreased the number of BEs in a dose-respondent manner. There was no increase in adverse
effects in the 20 mg group compared with lower doses or placebo [10]. This suggests that daily
administered, prophylactic treatment with tamoxifen (10–20 mg) is an effective treatment,
with an acceptable risk of minor side-effects [2,4,7,9,10,15].
Radiotherapy
RT has been used either as prophylactic or therapeutic treatment for BEs [11–14]. Three stud-
ies reported on prophylactic RT. Two studies reduced gynecomastia to 28–50%, compared to
control groups where 71–85% experienced gynecomastia [13,14]. Ozen et al. [11] reduced
gynecomastia to 15.8%, compared to a control group with an incidence of 50%. Two of the
studies reported a decrease of mastodynia to 36–43%, compared to control groups with an inci-
dence of 49–75%. Compared to no treatment or sham RT, prophylactic RT significantly
decreased the prevalence of gynecomastia to approximately one third of patients [11,13–16].
Nevertheless, RT was less effective than prophylactic tamoxifen, which in one study [8]
reduced gynecomastia to approximately 8% [15– 16]. Side effects following prophylactic RT
were present in one third of the patients, but these were usually mild and short-lived. Thera-
peutic RT results to be less effective than prophylactic RT. Van Poppel et al. [12] reported
improvement or resolution of gynecomastia in 7–26% of patients, while mastodynia improved
or resolved in 7–29%. Almost a quarter (21–24%) of patients actually experienced worsening of
symptoms. Side effects were in the range of 40% and these tended to be mild and transient
[12,15–16].
Table 5. Secondary outcome.
Publication Method Intervention Results Conclusion
Perdonà et al.
[15] Di Lorenzo
et al. [16]
Validated
questionnaire
(EORTC QLQ-c30)
Arm A: prophylactic
RT. Arm B: tamoxifen.
Arm C: control
No differences in mean global health
scores were found when comparing the
two intervention groups.
QoL was not negatively affected by either
treatment option.
Boccardo et al.
[7]
Self-adminstered,
validated
questionnaire.
Arm A: tamoxifen or
anastrozole. Arm B:
control
No differences between groups
concerning sexual interest. Minor
difference related to sexual functioning,
scores increased at 6-months for the
anastrozole and control groups while the
tamoxifen group remained unchanged.
Data on other domains were not
reported in detail.
No harmful effects on QoL were caused
by the addition of tamoxifen or
anastrozole to bicalutamide. Tamoxifen
did not worsen sexual interest or
functioning.
Fradet et al [10] Patients were
interviewed
Arm A: tamoxifen
daily (1–20 mg). Arm
B: placebo
Arm A: erectile dysfunction was lowest
in the 20 mg group (2.9%) and highest
in the 10 mg group (11.8%). Arm B:
erectile dysfunction in 3.3%.
No major differences in erectile
dysfunction between placebo and the
different tamoxifen doses.
Saltzstein et al.
[4]
Self-adminstered
questionnaire
Arm A: tamoxifen or
anastrozole daily.Arm
B: placebo
Fewer than 5% in all treatment groups
reported loss of libido or erectile
difficulties.
No evidence of increased sexual
dysfunction with either treatment.
doi:10.1371/journal.pone.0136094.t005
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Taking these findings together, prophylactic RT results to be more effective than therapeutic
RT, yet less effective than tamoxifen. The occurrence of RT related side effects is not negligible,
but they are mild and transient.
Quality of life
Boccardo et al. [7] reported no differences concerning sexual interest when comparing patients
treated with tamoxifen or anastrozole. There was an increase in sexual functioning scores in
the anastrozole and the control group at six months, while the tamoxifen group scores
remained unchanged. Authors concluded that the addition of tamoxifen or anastrozole to bica-
lutamide was not causing harmful effects to QoL, and that tamoxifen did not worsen sexual
interest or functioning. Perdonà et al. [15] and Di Lorenzo et al. [16] assessed QoL using the
EORTC QLQ-c30 questionnaire, which scores physical, role, emotional, cognitive, social func-
tions and overall health status. The questionnaire also contains a multi-item scale that scores
individual physical symptoms. Authors could not show any differences in mean global health
scores, when comparing tamoxifen to RT, thus concluding that no negative effect on QoL is
caused by any of the two treatment approaches.
Fradet et al. [10] found no differences concerning erectile dysfunction when comparing dif-
ferent doses of tamoxifen and placebo. These results are strengthened by Saltzstein et al. [4]
who reported no increase of sexual dysfunction from either tamoxifen or anastrozole. Both
authors conclude that no negative effect on sexual functioning is to be expected from tamoxifen
treatment for BEs.
Taking these findings together, no negative effects on QoL are to be expected from either
tamoxifen or RT, when managing BEs.
Discussion
Gynecomastia and/or mastodynia are very common medical problems in patients receiving
nonsteroidal antiandrogen treatment for prostate cancer. Different treatments are currently in
use. No systematic report on QoL following treatment for BEs is present in the literature.
In this review different treatments for nonsteroidal antiandrogen-induced gynecomastia
and/or mastodynia have been evaluated: tamoxifen had a significant effect on BEs, both as pro-
phylactic and as therapeutic treatment.
Studies comparing tamoxifen to treatment with the aromatase inhibitor anastrozole have
been evaluated. Anastrozole failed to provide any significant improvement in treating antian-
drogen-induced gynecomastia and/or mastodynia. When comparing prophylactic RT to
tamoxifen, tamoxifen appears to be the most effective treatment; however, only one study com-
pared these two treatments. The prophylactic treatment regime with daily administration of
tamoxifen 10–20 mg is showing the best results.
Within the articles selected, the number of patients reported was irrelevant to the final
assessment of the quality of evidence, since in these works the evidence was determined by
internal and external validity and precision.
Five studies concerning pharmacological treatment have been included [2,4,7,9,10], accord-
ing to The Cochrane Collaboration´s risk of bias tool: two have been classified as presenting
“low risk of bias”, two have “unclear risk of bias”, and one study has “high risk of bias”. No
description of the randomization process, blinding or allocation concealment is reasons for rat-
ing “unclear risk of bias”. Lack of blinding is the reason for “high risk of bias” in one study. The
quality of evidence of the studies concerning pharmacological treatment, and included in this
review was scored high (Table 3).
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Four studies concerning RT have been included [11–14]: one has been classified as present-
ing “low risk of bias”, while three have “high risk of bias.” No randomization, insufficient
description of randomization process, and no blinding, have been considered as factors to
increase the risk of bias. According to GRADE, this is sufficient enough to affect the internal
validity and thereby lead to serious study limitations, which leads to lower levels of evidence.
The quality of evidence of the studies concerning RT, and included in this review was scored
moderate (Table 3).
The study that compares RT to pharmacological treatment has been classified as presenting
“high risk of bias” as there is no blinding.
Two studies evaluating QoL [7,15–16] following gynecomastia treatment have “unclear”
and “high risk of bias”. One study has insufficient information on allocation concealment and
the other one has no blinding. This affects the internal validity of the studies and is enough to
downgrade the overall quality of evidence due to serious study limitations.
The quality of evidence of these studies concerning QoL following gynecomastia treatment,
and included in this review, is scored moderate (Table 3). Both studies used validated question-
naires to assess QoL outcomes; however, the questionnaires used were different; subsequently,
it is difficult to draw general conclusions from these results. Furthermore, QoL is reported only
as a secondary outcome in both articles. Further studies on QoL are needed.
Two more studies reported on sexual functioning and erectile problems [4,10]. Both studies
had “low risk of bias” and quality of evidence was scored high (Table 3).
Four of the five studies concerning pharmacological treatment [2,4,7,10], and two of the
four concerning RT [12,13], received financial support, or include co-authors that are directly
employed by the drug producing company (AstraZeneca). This represents, in fact, another pos-
sible source of bias that could affect the internal validity, but it was not given enough impor-
tance to impact the overall quality of evidence.
Future studies should be carefully designed in advance in order to minimize the risk of bias,
and to subsequently achieve higher quality of evidence. Authors are recommended to use ade-
quate allocation sequence generation and concealment, as well as blinding of participants, per-
sonnel and outcome assessors. All outcome data should be reported to avoid incomplete
reporting. To avoid selective reporting, a protocol with pre-specified outcomes should be avail-
able. All methods concerning study characteristics must be reported in the article to avoid
“unclear risk of bias” due to missing information.
This review has several limitations: it is limited to articles published in English only, and we
found no study concerning surgical treatment for BEs that matched inclusion criteria, thus
making it impossible to discuss surgical treatment.
Conclusions
The result from this systematic review is that the quality of evidence regarding the management
of BEs ranges from moderate to high.
Available evidence suggests that nonsteroidal induced gynecomastia and/or mastodynia can
be safely and effectively prevented in clinical practice with prophylactic tamoxifen (10–20 mg
daily) or RT. Tamoxifen can also be used as an effective therapeutic treatment. Tamoxifen
appears to be more effective in preventing gynecomastia and/or mastodynia than RT. No nega-
tive effect on QoL and/or sexual functioning is to be expected from tamoxifen when used for
antiandrogen-induced gynecomastia. Anastrozole is reported to be the least successful treat-
ment, and should not be recommended either as prophylactic or therapeutic treatment in clini-
cal practice for antiandrogen-induced gynecomastia. Future high quality studies with low risk
of bias are needed to further evaluate the effect on QoL in this patient group.
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